References

1. Reaven, G.M, Role of insulin resistance in human disease,1988(37), 1595-1607.
2. Alberti, K.G., Zimmet, P.Z., Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med,1998 (15), 539-553.
3. Alberti, K.G., Zimmet, P., Shaw, J., Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med,2006 (23), 469-480.
4. Park, Y.W., Zhu, S., Palaniappan, L., Heshka, S., Carnethon, M.R., Heymsfield, S.B., The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med, 2003. (163), 427-436.
5. Alexander, C.M., Landsman, P.B., Teutsch, S.M., Haffner, S.M., NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes, 2003b (52), 1210-1214.
6. Cook, S., Weitzman, M., Auinger, P., Nguyen, M., Dietz, W.H., Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med, 2003.(157), 821-827.
7. Alexander, C.M., The coming of age of the metabolic syndrome. Diabetes Care, 2003a.(26), 3180-3181.
8. Kendall, D.M., Harmel, A.P., The metabolic syndrome, type 2 diabetes, and cardiovascular disease: understanding the role of insulin resistance. Am J Manag Care, 2002(8), 635-53.
9. Hu, G., Qiao, Q., Tuomilehto, J., Balkau, B., Borch-Johnsen, K., Pyorala, K., Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med, 2004(164), 1066-1076.
10. Lakka, H.M., Laaksonen, D.E., Lakka, T.A., Niskanen, L.K., Kumpusalo, E., Tuomilehto, J., Salonen, J.T., The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men, JAMA, 2002(288), 2709-2716.

11. Bruno, G., Merletti, F., Biggeri, A., Bargero, G., Ferrero, S., Runzo, C., Prina Cerai, S., Pagano, G., Cavallo-Perin, P., Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study., Diabetes Care, 2004(27), 2689-2694.
12. Sowers, J.R.., Insulin resistance and hypertension, Am J Physiol Heart Circ Physiol, 2004 (286), H1597-H1602.
13. Sowers, J.R., Frohlich, E.D., Insulin and insulin resistance: impact on blood pressure and cardiovascular disease, Med Clin North Am, 2004(88), 63-82.
14. Hanley, A.J., Karter, A.J., Williams, K., Festa, A., D'Agostino, R.B. Jr, Wagenknecht, L.E., Haffner, S.M., Prediction of type 2 diabetes mellitus with alternative definitions of the metabolic syndrome: the Insulin Resistance Atherosclerosis Study, Circulation 2005 (112), 3713-3721.
15. Vuguin, P., Raab, E., Liu, B., Barzilai, N., Simmons, R.,. Hepatic insulin resistance precedes the development of diabetes in a model of intrauterine growth retardation, Diabetes 2004(53), 2617-2622.
16. Polonsky, K.S., Given, B.D., Van Cauter, E., Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects, J Clin Invest,1988(81), 442-448.
17. Wagenknecht, L.E., Langefeld, C.D., Scherzinger, A.L., Norris, J.M., Haffner, S.M., Saad, M.F., Bergman, R.N., Insulin sensitivity, insulin secretion, and abdominal fat: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study, Diabetes, 2003(52), 2490-2496.
18. Frontoni, S., Bracaglia, D., Gigli, F., Relationship between autonomic dysfunction, insulin resistance and hypertension, in diabetes, Nutr Metab Cardiovasc Dis, 2005(15), 441-449.
19. Sarafidis, P.A., Bakris, G.L., Insulin resistance, hyperinsulinemia, and hypertension: an epidemiologic approach, J Cardiometab Syndr, 2006 (1), 334-42.
20. Zarich, S.W., Cardiovascular risk factors in the metabolic syndrome: impact of insulin resistance on lipids, hypertension, and the development of diabetes and cardiac events, Rev Cardiovasc Med, 2005 (6), 194-205.

21. Caballero, A.E., Arora, S., Saouaf, R., Lim, S.C., Smakowski, P., Park, J.Y., King, G.L., LoGerfo, F.W., Horton, E.S., Veves, A., Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes, Diabetes, 1999(48), 1856-1862.

22. Brunzell, Dyslipidemia of the metabolic syndrome. R. Eckel, Editor. Obesity: Mechanisms and Clinical Management, Lippincott Williams and Wilkins, New York, 2002, 378-398.

23. Fujimoto, W.Y., Abbate, S.L., Kahn, S.E., Hokanson, J.E., Brunzell, J.D., The visceral adiposity syndrome in Japanese-American men, Obes Res, 1994 (2), 364-371.

24. Tchernof, A., Lamarche, B., Prud'Homme, D., Nadeau, A., Moorjani, S., Labrie, F., Lupien, P.J., Despres, J.P., The dense LDL phenotype. Association with plasma lipoprotein levels, visceral obesity, and hyperinsulinemia in men, Diabetes Care, 1996(19), 629-637.

25. DeFronzo, R.A., Pathogenesis of type 2 (non-insulin dependent) diabetes mellitus: a balanced overview, Diabetologia, 1992(35), 389-397.

26. DeFronzo, R.A., Bonadonna, R.C., Ferrannini, E., Pathogenesis of NIDDM. A balanced overview, Diabetes Care, 1992(15), 318-368.

27. Reviews on Indian Medicinal Plants, ICMR ,New Delhi, India, 2004, Vol II;215-220.

28. Wealth of India, A dictionary of Indian Raw Materials and Industrial product, NISCAIR, Council of Scientific and Industrial Research Press, India, Revised Edition Reprinted 2006, Vol I, 226-229.

29. Indian Medicinal Plant- A Compendium of 500 species, Orient Longman Pvt. Ltd., reprint 2005, Vol I;128-131.

30. The Ayurvedic Pharmacopoeia of India, Govt. of India, First edition, Part I, (II), 158-159.

31. Alam K, Pathak D, Ansari S. H., Evaluation of Anti-inflammatory Activity of *Ammomum subulatum* Fruit Extract, IJPSDR, 2011(l 3); 35-37.

32. Bisht V. K., Negi J. S., Bhandari A. K. and Sundriyal R. C., *Amomum subulatum* Roxb: Traditional, phytochemical and biological activities-An overview, African Journal of Agricultural Research, 2011(6); 5386-5390.

33. Shukla S.H., Mistry H. A., Patel V.G. and Jogi B.V., Pharmacognostical, Preliminary Phytochemical Studies And Analgesic Activity Of A*momum subulatum* roxb, An International Journal Of Pharmaceutical Sciences, 2010 (1), 90-102

34. Verma S.K., Rajeevan V., Bordia A. and Jain V., Greater Cardamom (*Amomum Subulatum* Roxb.) –A Cardio-Adaptogen Against Physical Stress, Journal of Herbal Medicine and Toxicology,2010 (4); 55-58.

35. Aneja K.R. and Joshi R., Antimicrobial Activity of *Amomum subulatum* and *Elettaria cardamomum* Against Dental Caries Causing Microorganisms, Ethnobotanical Leaflets, 2009 (13); 840-49.

36. Sen S, Chakraborty R, De B, Mazumder J. Plants and phytochemicals for peptic ulcer: An overview. Phcog Rev 2009(3); 270-279.

37. Yadav AS and Bhatnagar D, Modulatory effect of spice extracts on iron-induced lipid peroxidation in rat liver, Biofactors. 2007, 29(2-3);147-57

38. Joshi SC and Joshi V, Effect of Amomum subulatum on oxidative stress and atherosclerosis in cholesterol fed rabbits, Pharmacologyonline 2007(1); 451-463

39. Gilani SR, Shahid I , Javed M, Mehmud S and Ahmed R, Antimicrobial Activities and Physico-Chemical Properties of the Essential Oil from Amomum Subulatum, International Journal of Applied Chemistry 2006, (2); 81-86

40. Jamal A., Javed K., Aslam M., Jafri M.A., Gastroprotective effect of cardamom, Elettaria cardamomum Maton. fruits in rats, Journal of Ethnopharmacology, 2006 (103), 149-153.

41. Ravichandran G., Bharadwaj VS and Kolhapure SA, Evaluation of the efficacy and safety of "Anti-Wrinkle cream" in the treatment of facial skin wrinkles: A prospective, open, phase III clinical trial, The Antiseptic 2005,102(2); 65-70

42. Naik JP, Rao LJ, Mohan Kumar TM, Sampathu SR, Chemical composition of the volatile oil from the pericarp (husk) of large cardamom (Amomum subulatum Roxb.), Flavour and Fragrance Journal 2004, 19 (5);441-444.

43. Rout PK, Sahoo D, Jena KS and Rao YR, Analysis of the oil of large cardamom (Amomum subulatum Roxb.) growing in Sikkim, Journal of Essential Oil Research Jul/Aug 2003, (3); 20-24.

44. Jafri MA, Farah , Javed K and Singh S, Evaluation of the gastric antiulcerogenic effect of large cardamom (fruits of Amomum subulatum Roxb),J Ethnopharmacol. 2001, 75(2-3); 89-94.

45. Kikuzaki H, Kawai Y and Nakatani N, 1,1-Diphenyl-2-picrylhydrazyl radical-scavenging active compounds from greater cardamom (Amomum subulatum Roxb.), J Nutr Sci Vitaminol (Tokyo). 2001 Apr, 47(2);167-71.

46. Dhuley JN, Antioxidant effects of cinnamom *(Cinnamomiim vcrum)* bark and greater cardamom *(Amomum subulatum)* seeds in rats fed high fat diet. Indian J Exp Biol. 1999, (37); 238-242.

47. Qureshi S, Rai MK and Agrawal SC, *In vitro* evaluation of inhibitory nature of extracts of 18-plant species of Chhindwara against 3-keratinophilic fungi, Hindustan Antibiot Bull. 1997, 39(1-4); 56-60.

48. Gurudutt KN, Naik JP, Srinivas P and Ravindranath B, Volatile constituents of Large cardamom (Amomum subulatum Roxb.), Flav. Fragr. J. 1996, (11), 7-9.

49. Dubey NK and Mishra AK, Evaluation of some essential oil against dermatophytes. Indian Drugs 1990, (27); 529-531.

50. Singh PB, Medicinal Plants of Ayurvedic importance from Mandi district of Himachal Pradesh, Bull Med Ethnobot Res, 1993 (13); 126-136

51. Singh. PB and Aswal BS, Medicinal plants of Himachal Pradesh used in Indian pharmaceutical industry, Bull Med Ethnobot Res, 1992(13); 172-208.